In a phase 2 study, patients with FSGS and treatment-resistant MCD and increased urinary excretion of the biomarkers MCP1/Cr and/or TIMP1/Cr (markers for TNF-activation), are treated with anti-TNF-α mAb adalimumab (NCT04009668). This evidence concerns the gene TNF and focal segmental glomerulosclerosis.